Real Matters Reports Second Quarter Financial Results
(all amounts are expressed in millions of U.S. dollars, excluding per share amounts and unless otherwise stated) TORONTO–(BUSINESS WIRE)–Real Matters... Read more.
MarketAxess Reports First Quarter 2024 Financial Results
Record Emerging Markets, Eurobonds and Municipal Bonds Quarterly Commission Revenue NEW YORK–(BUSINESS WIRE)–MarketAxess Holdings Inc. (Nasdaq: MKTX),... Read more.
Aramark Reports Second Quarter Earnings
YEAR-OVER-YEAR SUMMARY Revenue +7%; Organic Revenue +9% Growth from strong base business volume, pricing actions, and net new business Record revenue in a second... Read more.
Enpro Reports First Quarter 2024 Results
First Quarter 2024 Highlights (All results reflect comparisons to prior-year period, from continuing operations, unless otherwise noted) (*Non-GAAP measure. See... Read more.
Premier, Inc. Reports Fiscal-Year 2024 Third-Quarter Results
Reaffirming fiscal 2024 financial guidance ranges Executed $400 million accelerated share repurchase transaction CHARLOTTE, N.C.–(BUSINESS WIRE)–Premier,... Read more.
Sage Therapeutics to Participate in Upcoming May Investor Conferences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain... Read more.
Ranger Energy Services, Inc. Announces Q1 2024 Results
HOUSTON–(BUSINESS WIRE)–Ranger Energy Services, Inc. (NYSE: RNGR) (“Ranger” or the “Company”) announced today its results for the first quarter... Read more.
Emerald Reports First Quarter 2024 Financial Results
Revenue Growth of 9.1% Year-over-Year Reaffirms FY 2024 Guidance NEW YORK–(BUSINESS WIRE)–Emerald Holding, Inc. (NYSE: EEX) (“Emerald” or the “Company”),... Read more.
Global Blue Releases the Monthly Tax Free Shopping Business Update for April 2024
Fresh data from Global Blue reveals that the global dynamic recovery for Tax Free Shopping accelerated across Continental Europe and Asia Pacific. Globally, issued... Read more.
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-up No signs or symptoms of overexpression toxicity,... Read more.